Similar Search Results

The impact of the entry of biosimilars : evidence from Europe

Scott Morton, Fiona; Stern, Ariel D.; Stern, Scott - 2017

Persistent link: https://www.econbiz.de/10011708133

Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Michaeli, Daniel; Michaeli, Christoph T. - In: The European journal of health economics 25 (2024) 6, pp. 979-997

Persistent link: https://www.econbiz.de/10014633366

Harmonizing regulatory market approval of products with high safety requirements : evidence from the European pharmaceutical market

Grünwald, Fabian; Stargardt, Tom - In: Health economics 33 (2024) 7, pp. 1546-1564

Persistent link: https://www.econbiz.de/10014566060

Pharmaceutical regulation in Europe and its impact on corporate R&D

Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9

Objectives: Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical...

Persistent link: https://www.econbiz.de/10010526909